Integrated Medical Model (IMM) 4.0 Verification and Validation (V & V) Testing by Reyes, D. et al.
National Aeronautics and Space AdministrationNational Aeronautics and Sp ce Administration
INTEGRATED MEDICAL MODEL (IMM) 4.0 
VERIFICATION AND VALIDATION (V&V) 
TESTING
M. Walton1, E. Kerstman2, J. Arellano3, L. Boley1, D. 
Reyes2, M. Young1, Y. Garcia1, L. Saile1, J. Myers4
1. Wyle Science, Technology & Engineering Group
2. University of Texas Medical Branch, Galveston, TX
3. MEI Technologies
4. NASA Glenn Research Center
www.nasa.gov
https://ntrs.nasa.gov/search.jsp?R=20160001729 2019-08-31T04:21:46+00:00Z
Presentation Overview
• IMM v3 versus IMM 4.0
• V&V Scope
• V&V Objectives
• Methods
• Results
• Summary
2National Aeronautics and Space Administration
IMM v3 versus IMM 4.0
3
Resource Utilization
 Cumulative
 Per disorder 
 Per crew member
Medical Condition 
Occurrences
 Cumulative 
 Per disorder 
 Per crew member
Crew Health Index (CHI)
 Cumulative 
 Per disorder 
 Per crew member
End States
 Loss of Crew Life (LOCL)
 Vehicle Evacuation (EVAC)
In-flight 
Medical 
Resources
 Quantity
 Mass
 Volume
 Power
 Cost
 Time
 Best-case 
Scenario
 Worst-case 
Scenario
 Clinical 
Guidelines
Medical
Condition
Incidence 
Data
 ISS/STS Medical 
Checklists
 “Delphi” Study 
Results
Medical 
Condition 
End States
 Functional 
Impairment
 Treatment 
Duration
 Best Case
 Worst Case
 Untreated Case
 Probability 
Distribution
 Evacuation
 Loss of Crew Life
 Best Case
 Worst Case
 Untreated Case
 Probability Distribution
 Literature Reviews
 Subject Matter 
Experts
Mission Profile 
& Constraints
Crew Profile
IMM Conceptual Model
Supporting Data IMM Inputs IMM Outputs
 Risk Factors
 Age
 Sex
 Dental
 Contacts
 History
 Crew #
 Duration
 EVA’s
 Mass
 Volume
Crew 
Functional 
Impairment
& Duration
IMM
Medical
Conditions Astronaut Data
 Analog Population
 General Population
 External Modules
 Bayesian Statistics
 Probability Distributions
 Best/Worst Case %
 Crew Risk Factors
 In-flight 
Astronaut Data
Clinical Findings Form
• Timeline – In addition to 
generating if conditions 
occur, IMM v4.0 
generates when 
conditions occur.
• Partial Treatment – IMM 
v4.0 gives partial credit 
for partial treatment in 
generating the outcomes 
of a condition
• Alternative Drug – If a 
primary drug required for 
treatment is not available, 
IMM v4.0 searches for 
medically appropriate 
substitutes.
V&V Scope
New capabilities were examined in a comparative, 
stepwise approach as follows:
• comparison of the current operational IMM v3 with 
the enhanced functionality of timeline (IMM 4.T)
• comparison of IMM 4.T with the enhanced 
functionalities of timeline and partial treatment 
capability (IMM 4.TPT)
• comparison of IMM 4.TPT with the enhanced 
functionalities of timeline, partial treatment and 
alternative medication capability (IMM 4.0)
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Verification Objectives
Confirm that the IMM version undergoing evaluation 
functioned correctly and that this IMM version performed 
appropriately when compared to the previous IMM 
version.
• Events are distributed as specified by the IMM.
– Incidence rate and proportion
– Event timing
– Best and worst case scenarios
– Evacuation (EVAC) and loss of crew life (LOCL) 
assignments
• Quality-adjusted mission time lost is being calculated 
correctly. 
• Resources are utilized and depleted correctly. 
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Validation Objectives
• Qualitative trend directions of the primary IMM outputs were 
hypothesized for mission scenario comparison of each successive 
implementation of new IMM capability. The following IMM primary 
outputs underwent quantitative evaluation and/or face validation to 
confirm that the IMM version undergoing evaluation functioned 
correctly, and that this IMM version performed as hypothesized 
when compared with each successive implementation of new IMM 
capability:
• Total medical events (TME)
• Crew health index (CHI)
• EVAC
• LOCL
• Resource utilization
• Face validation involves assessment of the model and/or its 
behavior by knowledgeable individuals to determine whether the 
model outputs are reasonable. Reasonable is defined as SME 
understanding of the directions and magnitudes of differences of 
the model and the RWS.
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Validation Objectives 
(Hypothesized Qualitative Trends for Primary Outputs)
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Enhanced Functionality TME CHI EVAC LOCL Resource Utilization 
 Expected effect on IMM 4.T outputs compared to IMM V3 
Timeline (IMM 4.T) ↓ ↑ ↓ ↓ ↓ 
 Expected effect on IMM 4.TPT outputs compared to IMM 4.T 
Partial Treatment  
(IMM 4.TPT) 
↑ ↑ ↓ ↓ ↑ 
 Expected effect on IMM 4.0 outputs compared to IMM 4.TPT 
Alternate Medications 
(IMM 4.0) 
↑ ↑ ↓ ↓ ↑ 
 
Methods
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Table 1: Design Reference Mission Characteristics 
Mission Duration 
Number of 2-person 
EVAs* 
Total 
EVAs 
EVA Schedule 
Lunar 
Sortie 
14 (days) 8 16 
every day from day 3 to day 
10 
ISS6 180 (days) 6 12 day 25, 50, 75, 100, 125, 150 
Mars 2.5 (years) 231 462 
every second day starting 
from day 180 
*Only two crew members are EVA eligible, 1 male, 1female (see Table 2 below) 
Table 2: Crew Characteristics 
 
Sex CAC EVA* Crowns Contacts Abdominal Surgery History 
Crew 1 M Yes No Yes No No 
Crew 2 M No Yes No No No 
Crew 3 M No No No Yes No 
Crew 4 M No No No Yes Yes 
Crew 5 F No Yes Yes No No 
Crew 6 F No No No Yes No 
*EVA schedule described in Table 1 
M- male(s); F- female(s); CAC- coronary artery calcium 
Results: TME 
(ISS6 DRM -MedCap Scenario)
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Results: CHI 
(ISS6 DRM -MedCap Scenario)
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Results: EVAC and LOCL 
(ISS6 DRM -MedCap Scenario)
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Results Summary
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Enhanced Functionality TME CHI EVAC LOCL Resource Utilization 
  IMM 4.T outputs compared to IMM V3 
Timeline (IMM 4.T) ↓ ↑ ↓ ↓ ↓ 
V3 106.41 90.36 0.1724 0.0051 739.29 
4.T 105.49 93.96 0.1418 0.0054 720.89 
 IMM 4.TPT outputs compared to IMM 4.T 
Partial Treatment (IMM 4.TPT) ↑ ↑ ↓ ↓ ↑ 
4.T 105.49 93.96 0.1418 0.0054 720.89 
4.TPT 105.97 94.87 0.0594 0.0043 724.09 
  IMM 4.0 outputs compared to IMM 4.TPT 
Alternate Medications (IMM 4.0) ↑ ↑ ↓ ↓ ↑ 
4.TPT 105.97 94.87 0.0594 0.0043 724.09 
4.0 106.02 94.92 0.0550 0.0042 723.41 
 
Summary
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• IMM 4.0 functionalities of timeline, partial treatment, and alternative 
treatments were added to IMM v3 to provide a closer approximation of 
the baselined real world system (i.e. the International Space Station). 
• V&V of these enhanced functionalities indicates that the IMM 4.0 
version is functioning correctly and performs as hypothesized based 
on meeting the proposed verification and validation objectives 
• Analysis confirmed: 
o medical events are distributed as specified by the IMM 
o quality-adjusted mission time lost is being calculated correctly
o resources are utilized and depleted correctly 
o total medical events, crew health index, probability of evacuation, 
and probability of loss of crew life were as hypothesized 
• Although original resource utilization hypotheses were not tested; 
subject matter expertise was used to evaluate the resources required-
with this consideration, no unacceptable findings were identified.
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• Verification: “…computational model 
accurately represents the underlying 
mathematical model…”
• Validation: “…determining the degree to 
which a model … is an accurate 
representation of the real world…”
• Credibility: “the quality to elicit belief or 
trust…”
Verification and Validation - DefinitionVV&C – Defining Terms for M&S
NASA-STD-7009, “Standard for Models and Simulations”, 2013.
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IMM Project VV&C History
• Medical Events
• Crew Impairment
• Loss of Crew Life
• Evacuation
• Resources Consumed
Probabilistic Risk Analysis / Monte Carlo Simulation
IMM
iMED Database
Resource
Optimization!
Scenario Definition (DRM)
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NASA-Standard-7009 (July 2008)
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National Aeronautics and Space Administration
19
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